Company news
Sol-gel Technologies Ltd. (NASDAQ:SLGL) news
Sol-gel Technologies Ltd. news releases on 6ix. Latest, Sep 30, 2026: Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
Press releases & updates
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
September 30, 2026
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
September 29, 2026
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
September 17, 2026
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 20, 2026
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 28, 2026
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
March 22, 2026
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
March 18, 2026
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
December 17, 2025
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 20, 2025
Sol-Gel Announces Health Canada Approval of EPSOLAY®
September 4, 2025
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 15, 2025
Sol-Gel Reports First Quarter 2025 Results
May 23, 2025
Sol-Gel Announces Reverse Share Split
May 1, 2025
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
April 17, 2025
Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects
February 3, 2025
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
November 19, 2024
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 14, 2024
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 15, 2024
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
July 24, 2024
Sol-Gel Technologies Announces Management Realignment
July 14, 2024
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
May 27, 2024
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 19, 2024
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
May 15, 2024
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
March 31, 2024
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
March 12, 2024
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
November 29, 2023
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
November 27, 2023
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 8, 2023
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
August 29, 2023
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 9, 2023
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
June 5, 2023
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 19, 2023
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
March 9, 2023
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
January 26, 2023
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
January 26, 2023
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 9, 2022
Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
October 2, 2022
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 3, 2022
Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
May 31, 2022
Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
May 16, 2022
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
April 24, 2022
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®
April 13, 2022
Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments
March 29, 2022
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
March 24, 2022
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference
December 21, 2021
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®
December 20, 2021
PreveCeutical Signs License Agreement for Exclusive Rights to Use UniQuest's Sol-Gel Technology for Delivery of Cannabinoids
November 17, 2021
Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
November 10, 2021